rs143862573
Variant summary
Our verdict is Likely benign. Variant got -4 ACMG points: 0P and 4B. BP4_Strong
The NM_020975.6(RET):c.2607+5G>A variant causes a splice donor 5th base, intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000254 in 1,612,278 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_020975.6 splice_donor_5th_base, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -4 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
RET | NM_020975.6 | c.2607+5G>A | splice_donor_5th_base_variant, intron_variant | ENST00000355710.8 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
RET | ENST00000355710.8 | c.2607+5G>A | splice_donor_5th_base_variant, intron_variant | 5 | NM_020975.6 | P4 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152102Hom.: 0 Cov.: 34
GnomAD3 exomes AF: 0.00000402 AC: 1AN: 248788Hom.: 0 AF XY: 0.00000741 AC XY: 1AN XY: 134992
GnomAD4 exome AF: 0.0000274 AC: 40AN: 1460176Hom.: 0 Cov.: 33 AF XY: 0.0000303 AC XY: 22AN XY: 726496
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152102Hom.: 0 Cov.: 34 AF XY: 0.00 AC XY: 0AN XY: 74290
ClinVar
Submissions by phenotype
Multiple endocrine neoplasia type 2A Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Apr 17, 2023 | This variant is classified as a variant of uncertain significance as there is insufficient evidence to determine its impact on protein function and/or cancer risk. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Counsyl | May 16, 2018 | - - |
Multiple endocrine neoplasia, type 2 Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 22, 2023 | This sequence change falls in intron 14 of the RET gene. It does not directly change the encoded amino acid sequence of the RET protein. It affects a nucleotide within the consensus splice site. This variant is present in population databases (rs143862573, gnomAD 0.003%). This variant has been observed in individual(s) with intestinal aganglionosis (PMID: 10090908, 33433679). ClinVar contains an entry for this variant (Variation ID: 372491). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Studies have shown that this variant is associated with altered splicing resulting in unknown protein product impact (PMID: 33433679). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | All of Us Research Program, National Institutes of Health | May 15, 2023 | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Nov 21, 2022 | Variant summary: RET c.2607+5G>A alters a non-conserved nucleotide located close to a canonical splice site and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. Several computational tools predict a significant impact on normal splicing: four predict the variant weakens a 5' donor site. At least one publication reported experimental evidence confirming that this variant affects mRNA splicing (Jiang_2021), however the protein level effect (i.e. residual function) of the variant cannot be predicted based on these data. The variant allele was found at a frequency of 4e-06 in 248788 control chromosomes (i.e. 1 carrier in the gnomAD v2.1 exomes dataset). The variant, c.2607+5G>A has been reported in the literature in an Italian individual affected with sporadic Hirschsprung Disease (HD) (Auricchio_1999). The variant was also reported in a child (Chinese) affected with total intestinal aganglionosis, who inherited the variant from the unaffected father (Jiang_2021). The authors proposed the presence of a risk haplotype contributing to the disease by "enhancing" the penetrance of this RET variant in the affected proband. These data indicate that the variant may be associated with disease. Four clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation, and all of them classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as a VUS-possibly pathogenic risk factor for Hirschsprung Disease. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Jul 30, 2024 | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis indicates that this variant does not alter splicing; This variant is associated with the following publications: (PMID: 25525159, 33433679, 35875156, 37002863, 10090908) - |
Hereditary cancer-predisposing syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 12, 2024 | The c.2607+5G>A intronic variant results from a G to A substitution 5 nucleotides after coding exon 14 in the RET gene. This nucleotide position is well conserved in available vertebrate species. This alteration was reported in an individual with sporadic Hirschprung's disease (Auricchio A et al. Am. J. Hum. Genet., 1999 Apr;64:1216-21). In silico splice site analysis predicts that this alteration will not have any significant effect on splicing. Based on the available evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at